US Tularemia Market

ID: MRFR/Pharma/18519-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026
US Tularemia Market Research Report By Type (ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, others), By Diagnosis (microscopy, immunochemistry, others), By Drugs (streptomycin, gentamicin, doxycycline, ciprofloxacin, others) and By End users (hospitals and clinics, academic and research centers, others) - Growth & Industry Forecast 2025 To 2035
US Tularemia Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.76%
2024 Market Size$ 30.66 Million
2025 Market Size$ 32.12 Million
2035 Market Size$ 51.13 Million
Key Players
Merck & Co
Sanofi
GlaxoSmithKline
Pfizer
Bayer AG
AbbVie
Trends
  • Rising Awareness and Education
  • Advancements in Diagnostic Technologies
  • Government Initiatives and Funding
Opportunities
  • Growing Veterinary Concerns
  • Research and Development Investments
  • Increased Incidence of Tularemia Cases
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Diagnosis Method (USD Million)
      1. 4.1.1 Serological Testing
      2. 4.1.2 Molecular Diagnostics
      3. 4.1.3 Culture Testing
      4. 4.1.4 Imaging Techniques
    2. 4.2 Life Sciences, BY Treatment Type (USD Million)
      1. 4.2.1 Antibiotic Therapy
      2. 4.2.2 Supportive Care
      3. 4.2.3 Surgical Intervention
    3. 4.3 Life Sciences, BY End-user (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Diagnostic Laboratories
      3. 4.3.3 Research Institutions
    4. 4.4 Life Sciences, BY Infection Type (USD Million)
      1. 4.4.1 Ulceroglandular Tularemia
      2. 4.4.2 Pneumonic Tularemia
      3. 4.4.3 Oculoglandular Tularemia
      4. 4.4.4 Typhoidal Tularemia
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Merck & Co (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 GlaxoSmithKline (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bayer AG (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AbbVie (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Novartis (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY END-USER
    5. 6.5 US MARKET ANALYSIS BY INFECTION TYPE
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
    18. 6.18 LIFE SCIENCES, BY INFECTION TYPE, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY INFECTION TYPE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
      4. 7.2.4 BY INFECTION TYPE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Tularemia Market Segmentation

US Tularemia Market By Diagnosis Method (USD Million, 2025-2035)

  • Serological Testing
  • Molecular Diagnostics
  • Culture Testing
  • Imaging Techniques

US Tularemia Market By Treatment Type (USD Million, 2025-2035)

  • Antibiotic Therapy
  • Supportive Care
  • Surgical Intervention

US Tularemia Market By End-user (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

US Tularemia Market By Infection Type (USD Million, 2025-2035)

  • Ulceroglandular Tularemia
  • Pneumonic Tularemia
  • Oculoglandular Tularemia
  • Typhoidal Tularemia

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.